Health Economics›Liposarcoma›All lines of therapy

All lines of therapy

Liposarcoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trabectedin monotherapy Variant #01	—	R 103 351	21d	—	~13.7 mo	~2	~R 206 702 PFS proxy · indirect	1
Eribulin monotherapy Variant #01	—	R 22 427	21d	—	~15.6 mo	~2	~R 44 854 PFS proxy · indirect	1
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	—	~10.8 mo	~2	~R 5 217 PFS proxy · indirect	2

3 of 3 regimens shown